WO2018135932A3 - Hmg-coa 환원효소 억제제 및 클로피도그렐을 포함하는 복합제제 - Google Patents

Hmg-coa 환원효소 억제제 및 클로피도그렐을 포함하는 복합제제 Download PDF

Info

Publication number
WO2018135932A3
WO2018135932A3 PCT/KR2018/001033 KR2018001033W WO2018135932A3 WO 2018135932 A3 WO2018135932 A3 WO 2018135932A3 KR 2018001033 W KR2018001033 W KR 2018001033W WO 2018135932 A3 WO2018135932 A3 WO 2018135932A3
Authority
WO
WIPO (PCT)
Prior art keywords
hmg
coa reductase
reductase inhibitor
clopidogrel
complex formulation
Prior art date
Application number
PCT/KR2018/001033
Other languages
English (en)
French (fr)
Other versions
WO2018135932A2 (ko
Inventor
백남현
최민수
김자영
우지영
성승규
송영준
서기수
허운
정태성
Original Assignee
동화약품주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동화약품주식회사 filed Critical 동화약품주식회사
Priority to MX2019009213A priority Critical patent/MX2019009213A/es
Priority to BR112019015107-9A priority patent/BR112019015107A2/pt
Priority to EP18741071.7A priority patent/EP3572075A2/en
Priority to CN201880008094.3A priority patent/CN110198705A/zh
Priority to JP2019560617A priority patent/JP2020507621A/ja
Priority to US16/479,861 priority patent/US20200129440A1/en
Publication of WO2018135932A2 publication Critical patent/WO2018135932A2/ko
Publication of WO2018135932A3 publication Critical patent/WO2018135932A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 클로피도그렐, HMG-CoA 환원효소 억제제 및 소수성 화합물을 함유한 분리막을 포함하는 복합제제에 관한 것이다. 보다 구체적으로 본 발명의 목적은 클로피도그렐과 HMG-CoA 환원효소 억제제를 포함하는 복합제제에 있어, HMG-CoA 환원효소 억제제의 안정성 저하를 막아 보관안정성이 우수한 심혈관계 질환 예방 또는 치료용 복합제제를 제공하는 것이다.
PCT/KR2018/001033 2017-01-23 2018-01-23 Hmg-coa 환원효소 억제제 및 클로피도그렐을 포함하는 복합제제 WO2018135932A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX2019009213A MX2019009213A (es) 2017-01-23 2018-01-23 Formulación compleja que comprende inhibidor de la hmg-coa reductasa y clopidogrel.
BR112019015107-9A BR112019015107A2 (pt) 2017-01-23 2018-01-23 Formulação de complexo compreendendo inibidor de hmg-coa redutase e clopidogrel
EP18741071.7A EP3572075A2 (en) 2017-01-23 2018-01-23 Complex formulation comprising hmg-coa reductase inhibitor and clopidogrel
CN201880008094.3A CN110198705A (zh) 2017-01-23 2018-01-23 包含hmg-coa还原酶抑制剂和氯吡格雷的复合制剂
JP2019560617A JP2020507621A (ja) 2017-01-23 2018-01-23 ＨＭＧ−ＣｏＡ還元酵素阻害剤およびクロピドグレルを含む複合製剤
US16/479,861 US20200129440A1 (en) 2017-01-23 2018-01-23 Complex formulation comprising hmg-coa reductase inhibitor and clopidogrel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0010532 2017-01-23
KR20170010532 2017-01-23

Publications (2)

Publication Number Publication Date
WO2018135932A2 WO2018135932A2 (ko) 2018-07-26
WO2018135932A3 true WO2018135932A3 (ko) 2018-09-27

Family

ID=62908979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/001033 WO2018135932A2 (ko) 2017-01-23 2018-01-23 Hmg-coa 환원효소 억제제 및 클로피도그렐을 포함하는 복합제제

Country Status (8)

Country Link
US (1) US20200129440A1 (ko)
EP (1) EP3572075A2 (ko)
JP (1) JP2020507621A (ko)
KR (1) KR102139346B1 (ko)
CN (1) CN110198705A (ko)
BR (1) BR112019015107A2 (ko)
MX (1) MX2019009213A (ko)
WO (1) WO2018135932A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100307268B1 (ko) * 1996-07-26 2001-09-24 디. 꼬쉬 티에노피리딘 유도체 및 ＨＭＧ-ＣｏＡ 환원효소 억제인자를 함유하는 항혈전성 및 항동맥경화성 약학적 조성물
JP2002506809A (ja) * 1998-03-18 2002-03-05 ブリストル−マイヤーズ スクイブ カンパニー スタチンおよびアスピリン含有医薬組成物
KR20090017423A (ko) * 2007-08-13 2009-02-18 한올제약주식회사 ＨＭＧ­ＣｏＡ 환원효소 저해제와 아스피린을 포함하는 복합제제 및 그의 제조방법
CN101985041A (zh) * 2010-11-08 2011-03-16 北京阜康仁生物制药科技有限公司 含有氯吡格雷和他汀类化合物的药物组合物
KR20110090060A (ko) * 2010-02-02 2011-08-10 한미홀딩스 주식회사 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 ＨＭＧ―ＣｏＡ 환원효소 억제제를 포함하는 복합제제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US260440A (en) 1882-07-04 peters
JPS5612114B2 (ko) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
ATE132496T1 (de) 1987-07-10 1996-01-15 Hoechst Ag 3-desmethyl-mevalonsäurederivate, verfahren zu ihrer herstellung, pharmazeutische präparate auf basis dieser verbindungen, ihre verwendung sowie zwischenprodukte
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4863957A (en) 1987-12-21 1989-09-05 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
FR2642065B1 (fr) 1989-01-24 1991-05-24 Lipha Derives d'acides benzocycloalcenyl dihydroxy alcanoiques, procede de preparation et medicaments les contenant
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
EP1424998B1 (en) * 2001-08-16 2010-05-26 The Trustees of The University of Pennsylvania Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20080026062A1 (en) * 2006-07-31 2008-01-31 Isaac Farr Pharmaceutical compositions including nano-sized active agent
EP2249815B1 (en) * 2008-01-25 2020-06-24 Laboratoires Majorelle Combinations of oral medicaments bonded by a wrapping

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100307268B1 (ko) * 1996-07-26 2001-09-24 디. 꼬쉬 티에노피리딘 유도체 및 ＨＭＧ-ＣｏＡ 환원효소 억제인자를 함유하는 항혈전성 및 항동맥경화성 약학적 조성물
JP2002506809A (ja) * 1998-03-18 2002-03-05 ブリストル−マイヤーズ スクイブ カンパニー スタチンおよびアスピリン含有医薬組成物
KR20090017423A (ko) * 2007-08-13 2009-02-18 한올제약주식회사 ＨＭＧ­ＣｏＡ 환원효소 저해제와 아스피린을 포함하는 복합제제 및 그의 제조방법
KR20110090060A (ko) * 2010-02-02 2011-08-10 한미홀딩스 주식회사 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 ＨＭＧ―ＣｏＡ 환원효소 억제제를 포함하는 복합제제
CN101985041A (zh) * 2010-11-08 2011-03-16 北京阜康仁生物制药科技有限公司 含有氯吡格雷和他汀类化合物的药物组合物

Also Published As

Publication number Publication date
BR112019015107A2 (pt) 2020-03-10
KR102139346B1 (ko) 2020-07-29
KR20180087190A (ko) 2018-08-01
US20200129440A1 (en) 2020-04-30
MX2019009213A (es) 2019-09-27
JP2020507621A (ja) 2020-03-12
CN110198705A (zh) 2019-09-03
WO2018135932A2 (ko) 2018-07-26
EP3572075A2 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
EP4364795A3 (en) Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
WO2017019429A8 (en) 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant idh1 inhibitors
MX2018006288A (es) Inhibidores de acc tipo ester y usos de los mismos.
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
MX2018006287A (es) Inhibidores de acc de triazol y usos de los mismos.
AU2018301696A8 (en) Heterocyclic inhibitors of ATR kinase
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
MX2015015416A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
AU2015275507A8 (en) Cyclic dipeptide-containing composition
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2015015162A (es) Agente de reduccion de acido urico.
WO2018218197A3 (en) ATR KINASE INHIBITORS BASED ON TETRAHYDROPYRIDO [4,3-D] PYRIMIDINE
WO2011056741A3 (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
WO2018135932A3 (ko) Hmg-coa 환원효소 억제제 및 클로피도그렐을 포함하는 복합제제
EP3461887A4 (en) COMPOSITION FOR PROLIFERATION, PROMOTION OF DIFFERENTIATION OR SENESCENCE INHIBITION OF STEM CELLS WITH JAK1 INHIBITOR AS AN ACTIVE SUBSTANCE
EP3512834A4 (en) INHIBIT OF BMP SIGNALING, CONNECTIONS, COMPOSITIONS AND USES THEREOF
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
EP4005569A3 (en) Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
PH12015502706A1 (en) Oral formulation for the treatment of cardiovascular diseases
WO2011096665A3 (en) Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor
AU2020378127A8 (en) Compounds as CD73 inhibitors
PH12017501897A1 (en) 2-thiopyrimidinones
TW201613892A (en) Forms and compositions of an ERK inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18741071

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019560617

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019015107

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2018741071

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112019015107

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190723